1Juutilainen A, Lehto S,Ronnemaa T, et al. Similarity of the impact of type 1 and type 2 diabetes on cardiovascularmortality in midrile-aged subjects. DiabeteS Care 2008,31 : 714 -719.
2Guntram S. Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Wicn Med Wochenschr 2010;160(1 -2): 8-19.
3Preis SR, Hwang S J, Coady S, et al. Trends in all - cause and cardiovascular disease mortality among women and men with and without diabetes mellims in the Framingham Heart Study, 1950 to 2005. Circulation 2009;119: 1728-1735.
4CY Pan, WY Yang, WP Jia, et al. Management of Chinese patients with type 2 diabetes, 1998 - 2006 : the Diabcare - China surveys. Current medical research and opinion 2009;25(1 ) :39 -45.
5Fontana L, Partridge L, Longo V D. Extending Healthy Life Span--From Yeast to Humans. Science 2010;328, 16 April: 321 - 326.
6IMAGE Study Group. Quality Indicators for the Prevention of Type 2 Diabetes in Europe - IMAGE. Horm Metab Res 2010;42 ( Suppl. I ) :S3 -S36.
7J Zhou, WP Jia, YQ Bao, et al. Glycemic variability and its responses to intensive insulin treatment in newly diagnosed type 2 diabetes. Med Sci Monit 2008; 14(11) : CR552 -558.
8Effect of intensive blood - glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352:854-65.
9Rodbard HW, Paul S J, Jaime AD, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control. Endocr Pratt 2009; 15:541 - 559.
